Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
| العنوان: | Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program |
|---|---|
| المؤلفون: | Sylvie Rottey, Joanna Van Erps, Joanna Vermeij, Patrick Werbrouck, Peter Schatteman, Bertrand Filleul, Lionel D'Hondt, W. Wynendaele, Fransien Van Hende, Dirk Schrijvers, Denis Schallier, Jean-Charles Goeminne, Gino Pelgrims, Els Everaert, Wim Demey, Filip Van Aelst, Jolanda Verheezen, Jean Pascal Machiels, Marika Rasschaert, Thierry Gil, Marylene Clausse, Charles Van Praet, Jan Van Haverbeke, Nicolaas Lumen, Jeroen Mebis |
| المساهمون: | Laboratory of Molecular and Medical Oncology, Department of Embryology and Genetics, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer |
| المصدر: | Urologic Oncology : seminars and original investigations, Vol. 34, no. 6, p. 254.e7-254.e13 (2016) Urologic oncology |
| بيانات النشر: | Elsevier Inc., 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Compassionate Use Trials, Male, medicine.medical_specialty, Urology, Abiraterone Acetate, Docetaxel, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Belgium, Prednisone, Interquartile range, Internal medicine, Humans, Medicine, 030212 general & internal medicine, Adverse effect, Aged, Retrospective Studies, business.industry, Abiraterone acetate, Common Terminology Criteria for Adverse Events, medicine.disease, Surgery, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Oncology, chemistry, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Taxoids, Human medicine, business, medicine.drug |
| الوصف: | Background: Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant prostate cancer (mCRPC). Real-world data on oncological outcome after AA are scarce. The current study assesses efficacy and safety of AA in mCRPC patients previously treated with docetaxel who started treatment during the Belgian compassionate use program (January 2011 July 2012). Patients and methods: Records from 368 patients with mCRPC from 23 different Belgian hospitals who started AA 1000 mg per day with 10 mg prednisone or equivalent were retrospectively reviewed (September 2013 December 2014). Prostate-specific antigen (PSA) response (decrease >= 50%), time to PSA progression (increase >50% over PSA nadir in case of PSA response/ >25% in absence of PSA response), time to radiographic progression (on bone scans or for soft tissue lesions using Response Evaluation Criteria In Solid Tumors 1.1), overall survival and adverse event rate (Common Terminology Criteria for Adverse Events v4.03) were analyzed. Kaplan-Meier statistics were applied. Results: Overall, 92 patients (25%) had an Eastern Cooperative Oncology Group performance status >= 2. Median age was 73 years, median PSA was 103 ng/dl. PSA response was observed in 131 patients (37.4%). Median time to PSA and radiographic progression was 4.1 months (95% CI: 3.6 /1.6) and 5.8 months (5.3-6.4), respectively. Median overall survival was 15.1 months (13.6-16.6). Most common grade 3 to 4 adverse events were anemia (13.9%), hypokalemia (7.3%), fatigue (6.8%), and pain (6.3%). Median duration of AA treatment was 5.3 months (interquartile range: 2.8-10.3). The main study limitation is its retrospective design. Conclusions: These real-world data on post-docetaxel AA efficacy are in line with the COU-AA-301 trial. Importantly, incidence of severe anemia and hypokalemia is up to 50% higher than reported in previous studies. (c) 2016 Elsevier Inc. All rights reserved. |
| اللغة: | English |
| تدمد: | 1078-1439 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6865f0f45657ada1d6ceab9ba0a47ee0 https://biblio.vub.ac.be/vubir/abiraterone-acetate-postdocetaxel-for-metastatic-castrationresistant-prostate-cancer-in-the-belgian-compassionate-use-program(5db35800-353a-4c9a-b822-366d75633640).html |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6865f0f45657ada1d6ceab9ba0a47ee0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10781439 |
|---|